Multicenter, therapeutic use observational study to evaluate the effects of concurrent therapy of Sarpogrelate on symptom improvement in patients with peripheral arterial disease

Kosin University Gospel Hospital0 个研究点目标入组 115 人开始时间: 待定最近更新: 2021年1月6日

试验速览

暂无简介。

•1. Patients between the ages of 19 and 80
•2. First administered or administered for less than three months of Sarpogrelate Hydrochloride to improve ischemic symptoms such as ulcers, pain and coldness caused by chronic arterial obstruction (Berger's disease, obstructive atherosclerosis, diabetic peripheral angiopathy, etc.)
•3. Written informed consent by patient or his/her legal representative and agreed to participate in the study approved by the Institutional Review Board or ethics Committee

•1. Overall life expectancy < 2 year.
•2. Any medically documented history of bleeding within a week of participating in the study
•3. Persons with diseases that may increase bleeding during the study (Hemophilia, Capillary Placebo, Gastrointestinal Ulcers, Urinary Tract Bleeding, Hemoglobin, Vitreous Hemorrhage, etc.)
•4. A female patient who is or may be pregnant
•5. Female patients who are or will be breastfeeding during the study period
•6. Patients who are not suitable for exercise therapy on their own due to cerebrovascular lesions, spinal diseases, muscle diseases, etc.
•7. Patients with severe renal or hepatic disease

发起方